Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 6/20 | 0.37 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.33 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.33 |
| ▸ | TNF | P01375 | 1/20 | 0.32 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.31 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.31 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.31 |
| ▸ | MIF | P14174 | 1/20 | 0.31 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.31 |
| ▸ | KDM1A | O60341 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29318135 | 0.92 | HTR2C (0.37) | HTR2CAAK1PDE4BMTNR1AMTNR1B | |
| SCHEMBL29318148 | 0.87 | HTR2C (0.36) | HTR2CFFAR4MTNR1AMTNR1B | |
| SCHEMBL29318139 | 0.86 | AAK1 (0.38) | HTR2CAAK1PDE4BMTNR1AMTNR1B | |
| SCHEMBL29318141 | 0.86 | HTR2C (0.35) | HTR2CAAK1 | |
| SCHEMBL29318121 | 0.81 | HTR2C (0.35) | HTR2CAAK1PDE4BFFAR4KDM1A | |
| SCHEMBL29318111 | 0.81 | HTR2C (0.35) | HTR2CAAK1PDE4BFFAR4KDM1A | |
| SCHEMBL29318113 | 0.81 | HTR2C (0.35) | HTR2CAAK1PDE4BFFAR4KDM1A | |
| SCHEMBL29318128 | 0.80 | CYP11B1 (0.41) | HTR2CPDE4BMTNR1AMTNR1BMIF | |
| SCHEMBL29318149 | 0.79 | AAK1 (0.36) | HTR2CAAK1PDE4B | |
| SCHEMBL29318567 | 0.73 | TSHR (0.42) | PDE4BMTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239756-A1 | NOVEL 3, 5-DISUBSTITUTED PYRIDINE AND 3, 5-DISUBSTITUTED PYRIDAZINE DERIVATIVES AND PHARMACEUTICAL USE OF SAME | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239756-A1 | NOVEL 3, 5-DISUBSTITUTED PYRIDINE AND 3, 5-DISUBSTITUTED PYRIDAZINE DERIVATIVES AND PHARMACEUTICAL USE OF SAME | ENPP2, SSB, PLPBP | HTR2C 1761/4885AAK1 2836/4885PDE4B 308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.